Placebo News and Research

RSS

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

Resveratrol counteracts exercise benefits in older men

In older men, a natural antioxidant compound found in red grapes and other plants -- called resveratrol -- blocks many of the cardiovascular benefits of exercise, according to research published today [22 July 2013] in The Journal of Physiology.

22 Jul 2013

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

Boston Scientific Corporation has launched a clinical trial to determine whether occipital nerve stimulation using the Precision System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications.

20 Jul 2013

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the marketing applications for the review of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis.

19 Jul 2013

Study supports topiramate as promising medication to treat addiction

The drug topiramate, typically used to treat epilepsy and more recently weight loss, may also help people addicted to both cocaine and alcohol use less cocaine, particularly heavy users, researchers in the department of Psychiatry at Penn Medicine report in a new study published in Drug and Alcohol Dependence.

19 Jul 2013

Computerized cognitive testing plays a key role in therapy development for dementia, AD

Computerized cognitive testing is increasingly playing a key role in therapy development for dementia and Alzheimer's disease. This week at the Alzheimer's Association International Conference, Keith Wesnes Ph.D., Practice Leader of Bracket and founder of the CDR System-, discussed new data for novel therapies at two poster presentations at the Alzheimer's Association International Conference.

19 Jul 2013

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

University of Arizona researchers have found in a recent study that ultrasound waves applied to specific areas of the brain appear able to alter patients' moods. The discovery has led the scientists to conduct further investigations with the hope that this technique could one day be used to treat conditions such as depression and anxiety.

19 Jul 2013

Oxytocin may not improve symptoms of children with autism, study finds

The so-called trust hormone, oxytocin, may not improve the symptoms of children with autism, a large study led by researchers at the University of New South Wales has found.

19 Jul 2013

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Duke Medicine researchers have identified biochemical changes in people taking antidepressants - but only in those whose depression improves. These changes occur in a neurotransmitter pathway that is connected to the pineal gland, the part of the endocrine system that controls the sleep cycle, suggesting an added link between sleep, depression and treatment outcomes.

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Common elderberry could be remedy for travellers susceptible to cold and flu, say researchers

The common elderberry could be just the remedy for international travellers susceptible to colds and bugs, according to researchers from the Griffith Health Institute.

17 Jul 2013

Combination therapy during cardiac arrest results in improved hospital discharge and neurological status

Among patients who experienced in-hospital cardiac arrest requiring vasopressors (drugs that increase blood pressure), use of a combination therapy during cardiopulmonary resuscitation resulted in improved survival to hospital discharge with favorable neurological status, according to a study in the July 17 issue of JAMA.

17 Jul 2013

Pre-diabetic patients who have substantial weight loss reduce their risk of type II diabetes

People with pre-diabetes who lose roughly 10 percent of their body weight within six months of diagnosis dramatically reduce their risk of developing type 2 diabetes over the next three years, according to results of research led by Johns Hopkins scientists.

17 Jul 2013

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

16 Jul 2013

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.

16 Jul 2013

Weill Cornell reports new findings from IVIG Phase 3 trial in Alzheimer's disease at AAIC 2013

Weill Cornell Medical College neurologist Dr. Norman Relkin reported new findings today from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease at the Alzheimer's Association International Conference in Boston, Mass.

16 Jul 2013

Placebo News and Research

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Resveratrol counteracts exercise benefits in older men

Boston Scientific initiates OPTIMISE trial to study ONS using Precision System for chronic migraine

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Study supports topiramate as promising medication to treat addiction

Computerized cognitive testing plays a key role in therapy development for dementia, AD

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

Oxytocin may not improve symptoms of children with autism, study finds

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Common elderberry could be remedy for travellers susceptible to cold and flu, say researchers

Combination therapy during cardiac arrest results in improved hospital discharge and neurological status

Pre-diabetic patients who have substantial weight loss reduce their risk of type II diabetes

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Weill Cornell reports new findings from IVIG Phase 3 trial in Alzheimer's disease at AAIC 2013

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News